Pub Date : 2022-04-13DOI: 10.2174/1573398x18666220413113142
A. Jangjou, Razieh Sadat Mousavi-roknabadi, H. Faramarzi, Alireza Neydani, Seyed Rouhollah Hosseini-Marvast, M. Moqadas
COVID-19 is known as a global health issue, which can cause high morbidity and mortality in patients. It is necessary to identify biomarkers, clinical and laboratory findings and effects on patients' mortality. This study aimed to evaluate the prognostic effect of clinical and laboratory findings on in-hospital mortality in patients with confirmed COVID-19. This retrospective cross-sectional study (February-August 2020) was conducted on adult patients with COVID-19, who were hospitalized in one of the main reference hospitals affiliated to Shiraz University of Medical Sciences, southern Iran. Patients with uncompleted or missed medical files were excluded from the study. Clinical and laboratory findings were extracted from the patients' medical files and then analyzed. The patients were categorized as survivor and nonsurvivors groups, and they were compared. Totally, 345 patients were enrolled that 205 (59.4%) were male. The mean±SD of age was 53.67±16.97 years, and 32 (9.3%) were died. Hypertension (28.4%) and diabetes (25.5%) were the most prevalent comorbidities. All clinical symptoms were similar in both groups, except fever, which was observed significantly more in nonsurvivors (P=0.027). The duration of hospitalization was 9.20±5.62 (range; 2-42) days, which was higher in nonsurvivors (P<0.001). The results of Multivariate Logistic Regression Model showed that CRP (OR=1.032, P=0.01) and INR (OR=48.88, P=0.049) were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19. The current study showed that in-hospital mortality was obtained as 9.3%. It was found that CRP and INR were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19.
{"title":"The prognostic effect of clinical and laboratory findings on in-hospital mortality in patients with confirmed COVID-19 disease","authors":"A. Jangjou, Razieh Sadat Mousavi-roknabadi, H. Faramarzi, Alireza Neydani, Seyed Rouhollah Hosseini-Marvast, M. Moqadas","doi":"10.2174/1573398x18666220413113142","DOIUrl":"https://doi.org/10.2174/1573398x18666220413113142","url":null,"abstract":"\u0000\u0000COVID-19 is known as a global health issue, which can cause high morbidity and mortality in patients. It is necessary to identify biomarkers, clinical and laboratory findings and effects on patients' mortality.\u0000\u0000\u0000\u0000This study aimed to evaluate the prognostic effect of clinical and laboratory findings on in-hospital mortality in patients with confirmed COVID-19.\u0000\u0000\u0000\u0000This retrospective cross-sectional study (February-August 2020) was conducted on adult patients with COVID-19, who were hospitalized in one of the main reference hospitals affiliated to Shiraz University of Medical Sciences, southern Iran. Patients with uncompleted or missed medical files were excluded from the study. Clinical and laboratory findings were extracted from the patients' medical files and then analyzed. The patients were categorized as survivor and nonsurvivors groups, and they were compared.\u0000\u0000\u0000\u0000Totally, 345 patients were enrolled that 205 (59.4%) were male. The mean±SD of age was 53.67±16.97 years, and 32 (9.3%) were died. Hypertension (28.4%) and diabetes (25.5%) were the most prevalent comorbidities. All clinical symptoms were similar in both groups, except fever, which was observed significantly more in nonsurvivors (P=0.027). The duration of hospitalization was 9.20±5.62 (range; 2-42) days, which was higher in nonsurvivors (P<0.001). The results of Multivariate Logistic Regression Model showed that CRP (OR=1.032, P=0.01) and INR (OR=48.88, P=0.049) were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19.\u0000\u0000\u0000\u0000The current study showed that in-hospital mortality was obtained as 9.3%. It was found that CRP and INR were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42089312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-11DOI: 10.2174/1573398x18666220411121046
A. Hosseininasab, R. Sinaei, S. Ebrahimi, S. Parvaresh, M. Jafari
The coronavirus disease 2019 (COVID‐19) was first reported in December 2019 in Wuhan, China. Skin manifestations of COVID-19 have been reported sporadically. Staphylococcus aureus occurs after viral infection due to unregulated IFN-α. We designed this reported case to pay more attention to the rare skin manifestations following COVID-19. The patient was a 12-months-old girl who presented with fever and skin rashes. Two days before admission, erythematous rashes spread around the mouth, nose, eyes, and trunk. Erythematous lesions begin to peel the next day. RT-PCR of the nasopharynx was positive for COVID-19. Treatment with vancomycin and clindamycin was started. The patient was discharged with complete recovery of skin lesions. One of the early manifestations of COVID-19 in children can be fever and rash. Clinical suspicion led to more attention to complications of bacterial superinfection such as staphylococcal scalded skin syndrome.
{"title":"Cutaneous manifestations of Novel coronavirus disease (COVID-19): A case with staphylococcal scalded skin syndrome (SSSS)","authors":"A. Hosseininasab, R. Sinaei, S. Ebrahimi, S. Parvaresh, M. Jafari","doi":"10.2174/1573398x18666220411121046","DOIUrl":"https://doi.org/10.2174/1573398x18666220411121046","url":null,"abstract":"\u0000\u0000The coronavirus disease 2019 (COVID‐19) was first reported in December 2019 in Wuhan, China. Skin manifestations of COVID-19 have been reported sporadically. Staphylococcus aureus occurs after viral infection due to unregulated IFN-α. We designed this reported case to pay more attention to the rare skin manifestations following COVID-19.\u0000\u0000\u0000\u0000The patient was a 12-months-old girl who presented with fever and skin rashes. Two days before admission, erythematous rashes spread around the mouth, nose, eyes, and trunk. Erythematous lesions begin to peel the next day. RT-PCR of the nasopharynx was positive for COVID-19. Treatment with vancomycin and clindamycin was started. The patient was discharged with complete recovery of skin lesions.\u0000\u0000\u0000\u0000One of the early manifestations of COVID-19 in children can be fever and rash. Clinical suspicion led to more attention to complications of bacterial superinfection such as staphylococcal scalded skin syndrome.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49606580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-11DOI: 10.2174/1573398x18666220411123508
S. Covantsev, O. Corlateanu, Stanislav I. Volkov, R. Uzdenov, V. Botnaru, A. Corlateanu
: One of the important comorbidities that has a longstanding research history in COPD is diabetes. Although there are multiple studies on COPD and diabetes the exact links between these two conditions is still controversial. The exact prevalence of diabetes in COPD varies between 2 and 37 %. The true nature of this relationship is complex and may be partially related to the traditional risk factors for diabetes such as smoking, cardiovascular disease and use of steroids. However, COPD is a disease that has multiple phenotypes and is no longer regarded as a homogeneous condition. It seems that some COPD patients who have overlap with asthma or the obese phenotype at a particular risk for T2DM. The aim of this review is to analyze the prevalence, risk factors and possible interactions between COPD and diabetes mellitus.
{"title":"COPD and diabetes mellitus: down the rabbit hole","authors":"S. Covantsev, O. Corlateanu, Stanislav I. Volkov, R. Uzdenov, V. Botnaru, A. Corlateanu","doi":"10.2174/1573398x18666220411123508","DOIUrl":"https://doi.org/10.2174/1573398x18666220411123508","url":null,"abstract":"\u0000\u0000: One of the important comorbidities that has a longstanding research history in COPD is diabetes. Although there are multiple studies on COPD and diabetes the exact links between these two conditions is still controversial. The exact prevalence of diabetes in COPD varies between 2 and 37 %. The true nature of this relationship is complex and may be partially related to the traditional risk factors for diabetes such as smoking, cardiovascular disease and use of steroids. However, COPD is a disease that has multiple phenotypes and is no longer regarded as a homogeneous condition. It seems that some COPD patients who have overlap with asthma or the obese phenotype at a particular risk for T2DM. The aim of this review is to analyze the prevalence, risk factors and possible interactions between COPD and diabetes mellitus.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46120639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-07DOI: 10.2174/1573398x18666220407084457
Daniel Maranatha, Devi Ambarwati
Histopathological abnormalities of pulmonary tuberculosis (TB) include caseous granuloma formation, tissue damage, and cavity formation, all of which could lead to permanent changes in the pulmonary anatomy. In pulmonary TB, an increase in serum Matrix Metalloproteinase (MMP)-9 correlates with disease severity and worse prognosis. This study aims to analyze the association between serum MMP-9 levels and the values of FVC, FEV1, and FEV1/FVC. A cross-sectional study of patients with pulmonary tuberculosis was conducted in the Tuberculosis Outpatient Clinic, Dr. Soetomo Academic Hospital, Surabaya, Indonesia. Spirometry and serum MMP-9 levels were examined in new pulmonary TB patients prior to anti-tuberculosis therapy. The relationship between serum MMP-9 levels and results of spirometry examination was then analyzed. There were 44 new pulmonary TB cases with a mean age of 37.90 ± 15.15 years. The patients who experienced symptoms in < 1 month were 20.5%, ≥ 1 month 59.1%, and ≥ 2 months 20.4%. The mean MMP-9 serum level was 11.27±5.47 ng/ml. Spirometry results: FVC 1.83±0.69 L, FVC predicted 56.24±18.74%, FEV1 1.71±0.72 L/sec, FEV1 predicted 60.85±21.30%, and FEV1/FVC 104.16 ± 17.45%. In pulmonary TB patients with symptoms experienced in < 1 month to diagnosis, a significant relationship between MMP-9 and FVC levels was found with r = -0.839 (p = 0.005). There is a correlation between serum MMP-9 level and restrictive pulmonary impairment in new pulmonary TB cases with symptoms experienced in < 1 month.
{"title":"Association of serum MMP-9 level and lung function in new pulmonary tuberculosis case","authors":"Daniel Maranatha, Devi Ambarwati","doi":"10.2174/1573398x18666220407084457","DOIUrl":"https://doi.org/10.2174/1573398x18666220407084457","url":null,"abstract":"\u0000\u0000Histopathological abnormalities of pulmonary tuberculosis (TB) include caseous granuloma formation, tissue damage, and cavity formation, all of which could lead to permanent changes in the pulmonary anatomy. In pulmonary TB, an increase in serum Matrix Metalloproteinase (MMP)-9 correlates with disease severity and worse prognosis. This study aims to analyze the association between serum MMP-9 levels and the values of FVC, FEV1, and FEV1/FVC.\u0000\u0000\u0000\u0000A cross-sectional study of patients with pulmonary tuberculosis was conducted in the Tuberculosis Outpatient Clinic, Dr. Soetomo Academic Hospital, Surabaya, Indonesia. Spirometry and serum MMP-9 levels were examined in new pulmonary TB patients prior to anti-tuberculosis therapy. The relationship between serum MMP-9 levels and results of spirometry examination was then analyzed.\u0000\u0000\u0000\u0000There were 44 new pulmonary TB cases with a mean age of 37.90 ± 15.15 years. The patients who experienced symptoms in < 1 month were 20.5%, ≥ 1 month 59.1%, and ≥ 2 months 20.4%. The mean MMP-9 serum level was 11.27±5.47 ng/ml. Spirometry results: FVC 1.83±0.69 L, FVC predicted 56.24±18.74%, FEV1 1.71±0.72 L/sec, FEV1 predicted 60.85±21.30%, and FEV1/FVC 104.16 ± 17.45%. In pulmonary TB patients with symptoms experienced in < 1 month to diagnosis, a significant relationship between MMP-9 and FVC levels was found with r = -0.839 (p = 0.005).\u0000\u0000\u0000\u0000There is a correlation between serum MMP-9 level and restrictive pulmonary impairment in new pulmonary TB cases with symptoms experienced in < 1 month.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48040193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-18DOI: 10.2174/1573398x18666220218101742
A. Abumossalam, T. Abdelgawad, Mohamad Abomesllam Ibrahim, Mohamad Darwish Mohamad, Dalia Abdelsattar Ahmed, Hanan Abdelsattar Elhalaby
COVID-19 has still expressed as a mysterious viral infection with dramatic pulmonary consequences. This article aims to study the radiological pulmonary consequences of respiratory covid-19 infection at 6 months and their relevance to the clinical stage, laboratory markers, and management modalities. This study was implemented on two hundred and fifty (250) confirmed positive cases for COVID-19 infections. One hundred and ninety-seven cases (197) who completed the study displayed residual radiological lung shadowing (RRLS) on follow-up computed tomography (CT) of the chest. They were categorized by Simple clinical classification of COVID-19 into groups A, B and C. GGO as well as reticulations were statistically significantly higher in group A than other two groups; however, bronchiectasis changes, parenchymal scarring, nodules as well as pleural tractions were statistically significantly higher in group C than the other two groups. Respiratory covid-19 infection might be linked to residual radiological lung shadowing. Ground glass opacities GGO, reticulations pervaded in mild involvement with lower inflammatory markers level, unlike, severe changes that expressed scarring, nodules and bronchiectasis changes accompanied by increased levels of inflammatory markers.
{"title":"COVID Tarnish Lung: Residual Radiological Lung Consequences of Infection with COVID-19","authors":"A. Abumossalam, T. Abdelgawad, Mohamad Abomesllam Ibrahim, Mohamad Darwish Mohamad, Dalia Abdelsattar Ahmed, Hanan Abdelsattar Elhalaby","doi":"10.2174/1573398x18666220218101742","DOIUrl":"https://doi.org/10.2174/1573398x18666220218101742","url":null,"abstract":"\u0000\u0000COVID-19 has still expressed as a mysterious viral infection with dramatic pulmonary consequences.\u0000\u0000\u0000\u0000This article aims to study the radiological pulmonary consequences of respiratory covid-19 infection at 6 months and their relevance to the clinical stage, laboratory markers, and management modalities.\u0000\u0000\u0000\u0000This study was implemented on two hundred and fifty (250) confirmed positive cases for COVID-19 infections. One hundred and ninety-seven cases (197) who completed the study displayed residual radiological lung shadowing (RRLS) on follow-up computed tomography (CT) of the chest. They were categorized by Simple clinical classification of COVID-19 into groups A, B and C.\u0000\u0000\u0000\u0000GGO as well as reticulations were statistically significantly higher in group A than other two groups; however, bronchiectasis changes, parenchymal scarring, nodules as well as pleural tractions were statistically significantly higher in group C than the other two groups.\u0000\u0000\u0000\u0000Respiratory covid-19 infection might be linked to residual radiological lung shadowing. Ground glass opacities GGO, reticulations pervaded in mild involvement with lower inflammatory markers level, unlike, severe changes that expressed scarring, nodules and bronchiectasis changes accompanied by increased levels of inflammatory markers.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47616509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-17DOI: 10.2174/1573398x18666220217151152
Ashima Panchal, Jigar Panchal, Sonika Jain, J. Dwivedi
PAH was first of all reported from German Doctor E. Romberg in 1891, It's usually found throughout the globe, but it is a burden in India and other developing countries. Pulmonary arterial hypertension (PAH) is characterized by a rise in pulmonary arterial pressure and the development of progressive symptoms like reduction in functional ability, shortness of breath and fatigue. The pulmonary arteries move blood from the right side of the heart over the lungs. Increase pressure in pulmonary arteries known as pulmonary arterial pressure (PAH). The treatment of is require because without it, the right heart to work much harder due to high blood pressure in the lungs, and over time it became reason of heart failure. In this article, we have tried to provide brief information about the prevalence, pathology, classification and different therapies of PAH. Combining medicines from different categories is currently given as quality care and has been revealed to boost outcomes. A small part of the new treatment options has been included.
{"title":"A literature review on pulmonary arterial hypertension (PAH)","authors":"Ashima Panchal, Jigar Panchal, Sonika Jain, J. Dwivedi","doi":"10.2174/1573398x18666220217151152","DOIUrl":"https://doi.org/10.2174/1573398x18666220217151152","url":null,"abstract":"\u0000\u0000PAH was first of all reported from German Doctor E. Romberg in 1891, It's usually found throughout the globe, but it is a burden in India and other developing countries. Pulmonary arterial hypertension (PAH) is characterized by a rise in pulmonary arterial pressure and the development of progressive symptoms like reduction in functional ability, shortness of breath and fatigue. The pulmonary arteries move blood from the right side of the heart over the lungs.\u0000\u0000\u0000\u0000Increase pressure in pulmonary arteries known as pulmonary arterial pressure (PAH). The treatment of is require because without it, the right heart to work much harder due to high blood pressure in the lungs, and over time it became reason of heart failure. In this article, we have tried to provide brief information about the prevalence, pathology, classification and different therapies of PAH. Combining medicines from different categories is currently given as quality care and has been revealed to boost outcomes. A small part of the new treatment options has been included.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45169099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-17DOI: 10.2174/1573398x18666220217151845
A. Papi, K. Kostikas, I. Nikolaev, I. Kottakis
Despite the wide range of available therapies, asthma remains uncontrolled in 40–65% of patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is recommended in the Global Initiative for Asthma 2021 report for patients across all asthma severities, with treatment options combining an ICS with a long-acting β2-agonist (LABA) or a LABA and a long-acting muscarinic antagonist (LAMA), depending on disease severity. Based on this, the availability of single inhaler fixed-dose ICS/LABA/LAMA combination is a major need in asthma management. Indacaterol acetate/glycopyrronium bromide/mometasone furoate has been developed as a once-daily inhaled asthma treatment that combines an ICS (mometasone furoate), a LABA (indacaterol acetate) and a LAMA (glycopyrronium bromide) in a formulation delivered using the dry powder inhaler Breezhaler®, for patients with uncontrolled asthma on medium- or high-dose ICS/LABA. This article provides an overview of the different and complementary mechanisms of action, and the clinical effectiveness of the monocomponents of the indacaterol/glycopyrronium/mometasone furoate fixed combination, and highlights the benefits of using the three agents in combination in patients with moderate and severe asthma.
{"title":"Indacaterol acetate/glycopyrronium bromide/mometasone furoate: a combination therapy for asthma","authors":"A. Papi, K. Kostikas, I. Nikolaev, I. Kottakis","doi":"10.2174/1573398x18666220217151845","DOIUrl":"https://doi.org/10.2174/1573398x18666220217151845","url":null,"abstract":"\u0000\u0000Despite the wide range of available therapies, asthma remains uncontrolled in 40–65% of patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is recommended in the Global Initiative for Asthma 2021 report for patients across all asthma severities, with treatment options combining an ICS with a long-acting β2-agonist (LABA) or a LABA and a long-acting muscarinic antagonist (LAMA), depending on disease severity. Based on this, the availability of single inhaler fixed-dose ICS/LABA/LAMA combination is a major need in asthma management. Indacaterol acetate/glycopyrronium bromide/mometasone furoate has been developed as a once-daily inhaled asthma treatment that combines an ICS (mometasone furoate), a LABA (indacaterol acetate) and a LAMA (glycopyrronium bromide) in a formulation delivered using the dry powder inhaler Breezhaler®, for patients with uncontrolled asthma on medium- or high-dose ICS/LABA. This article provides an overview of the different and complementary mechanisms of action, and the clinical effectiveness of the monocomponents of the indacaterol/glycopyrronium/mometasone furoate fixed combination, and highlights the benefits of using the three agents in combination in patients with moderate and severe asthma.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49065347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-10DOI: 10.2174/1573398x18666220210145349
M. S. Fekri, E. Barfzade, Mehrdad Farokhniab, S. M. H. Bajgani, A. Shafahi, Mohsen Shafiepourb, Sajjadeh Movahediniac, Shariar Dabirid, Meysam Yousefi
COVID-19 is an infectious disease caused by SARS-CoV-2 and can lead to acute respiratory distress. We aimed to investigate the association between COVID-19 severity and serum apelin-17 and inflammatory mediator levels. This cross-sectional study was conducted on patients with COVID-19. COVID-19 infection was confirmed by the RT-PCR test. The patients' data were extracted from their records. Venous blood samples were obtained from the patients to investigate the serum levels of apelin-17 and inflammatory mediators. Results: Eighty-six COVID-19 patients were studied. The mean age of the participants was 55.56±14.88, and 43 (50%) were male. Clinical symptoms were dyspnea 77.6%, fever 52.3%, cough 48.8%, gastrointestinal symptoms 15.1%, and chest pain 7%. The overall mortality rate was 7%. No significant relationship was found between serum apelin-17 levels and COVID-19 severity (P= 0.48). However, there was a significant and direct relationship between COVID-19 severity and serum levels of CRP (P= 0.038) and D-dimer (P= 0.029). Serum apelin-17 levels were higher in recovered patients than those who died (4.90 vs. 3.19). Moreover, serum apelin-17 levels were higher in the patients admitted to the general ward than those admitted to the ICU (5.15 vs. 3.98). The difference was not statistically significant. However, there was a significant and direct relationship between serum apelin-17 levels and lymphocyte count (P= 0.022). Moreover, there was a significant and inverse relationship between lymphocyte count and COVID-19 severity (P= 0.004). Therefore, it can be interpreted that COVID-19 severity may decrease with an increase in serum apelin-17 levels. Therefore, to prove this hypothesis, a study with larger sample size is recommended.
{"title":"Investigating COVID-19 Severity Based on Serum Apelin-17 levels and Inflammatory Mediators","authors":"M. S. Fekri, E. Barfzade, Mehrdad Farokhniab, S. M. H. Bajgani, A. Shafahi, Mohsen Shafiepourb, Sajjadeh Movahediniac, Shariar Dabirid, Meysam Yousefi","doi":"10.2174/1573398x18666220210145349","DOIUrl":"https://doi.org/10.2174/1573398x18666220210145349","url":null,"abstract":"\u0000\u0000COVID-19 is an infectious disease caused by SARS-CoV-2 and can lead to acute respiratory distress.\u0000\u0000\u0000\u0000We aimed to investigate the association between COVID-19 severity and serum apelin-17 and inflammatory mediator levels.\u0000\u0000\u0000\u0000This cross-sectional study was conducted on patients with COVID-19. COVID-19 infection was confirmed by the RT-PCR test. The patients' data were extracted from their records. Venous blood samples were obtained from the patients to investigate the serum levels of apelin-17 and inflammatory mediators.\u0000\u0000\u0000\u0000Results: Eighty-six COVID-19 patients were studied. The mean age of the participants was 55.56±14.88, and 43 (50%) were male. Clinical symptoms were dyspnea 77.6%, fever 52.3%, cough 48.8%, gastrointestinal symptoms 15.1%, and chest pain 7%. The overall mortality rate was 7%. No significant relationship was found between serum apelin-17 levels and COVID-19 severity (P= 0.48). However, there was a significant and direct relationship between COVID-19 severity and serum levels of CRP (P= 0.038) and D-dimer (P= 0.029).\u0000\u0000\u0000\u0000Serum apelin-17 levels were higher in recovered patients than those who died (4.90 vs. 3.19). Moreover, serum apelin-17 levels were higher in the patients admitted to the general ward than those admitted to the ICU (5.15 vs. 3.98). The difference was not statistically significant. However, there was a significant and direct relationship between serum apelin-17 levels and lymphocyte count (P= 0.022). Moreover, there was a significant and inverse relationship between lymphocyte count and COVID-19 severity (P= 0.004). Therefore, it can be interpreted that COVID-19 severity may decrease with an increase in serum apelin-17 levels. Therefore, to prove this hypothesis, a study with larger sample size is recommended.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49348403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-08DOI: 10.2174/1573398x18666220208102258
I. Ghasemzadeh, M. Mardani, Nasrinsadat Mirtalaee, Ghazal Sanadgol, Sara Abolghasemi
Since emerged in December 2019, in China, COVID-19 has become a major concern for people and health-care systems. Patients with medical diseases are at a higher risk of severe disease development and mortality. Cancer patients are more vulnerable to infections. Several studies demonstrated that COVID-19 is associated with a greater risk of morbidity and mortality among cancer patients. However, the risk factors for mortality among these patients are still unknown. This study aimed to identify the risk factors associated with in-hospital death among cancer patients with COVID-19. In this cross-sectional study, we analyzed demographic data, clinical characteristics and laboratory parameters of cancer patients with COVID-19 who were hospitalized in three tertiary referral hospitals in Tehran, Iran from February to May 2020. Diagnosis of COVID-19 was confirmed using real-time polymerase chain reaction testing and computed tomography scan findings. Data analysis was performed using SPSS software, version 20. P-value less than 0.05 was considered significant. Sixty-six cancer patients with COVID-19 were enrolled in this study. Among participants, 35 (53.03%) patients discharged and 31 (46.97%) patients died in hospital. Thirty-two (48.4%) patients suffered from hematologic and 34 (51.6%) from non-hematologic cancers. The most common comorbidities were hypertension (68.18%) and diabetes (56.06%). The most common symptoms among patients were rhinorrhea (59.1%), fever (54.5%) and dyspnea (48.4%), respectively. Diabetes (p= 0.00), hypoxemia (p= 0.005) and receiving chemotherapy or radiotherapy during the last three months (p= 0.022) were associated with a significantly greater risk of in-hospital mortality. Hypoxemia, diabetes and the time interval between chemotherapy/radiotherapy and hospitalization is associated with a higher risk of in-hospital mortality among cancer patients with COVID-19. These risk factors should be considered in clinical management hospitalized COVID19 patients who suffer from cancers. Regarding the risk factors may help to reduce in-hospital mortality and poor outcomes.
{"title":"Risk factors for in-hospital mortality among cancer patients with COVID-19: A cross-sectional study","authors":"I. Ghasemzadeh, M. Mardani, Nasrinsadat Mirtalaee, Ghazal Sanadgol, Sara Abolghasemi","doi":"10.2174/1573398x18666220208102258","DOIUrl":"https://doi.org/10.2174/1573398x18666220208102258","url":null,"abstract":"\u0000\u0000Since emerged in December 2019, in China, COVID-19 has become a major concern for people and health-care systems. Patients with medical diseases are at a higher risk of severe disease development and mortality. Cancer patients are more vulnerable to infections. Several studies demonstrated that COVID-19 is associated with a greater risk of morbidity and mortality among cancer patients. However, the risk factors for mortality among these patients are still unknown.\u0000\u0000\u0000\u0000This study aimed to identify the risk factors associated with in-hospital death among cancer patients with COVID-19.\u0000\u0000\u0000\u0000In this cross-sectional study, we analyzed demographic data, clinical characteristics and laboratory parameters of cancer patients with COVID-19 who were hospitalized in three tertiary referral hospitals in Tehran, Iran from February to May 2020. Diagnosis of COVID-19 was confirmed using real-time polymerase chain reaction testing and computed tomography scan findings. Data analysis was performed using SPSS software, version 20. P-value less than 0.05 was considered significant.\u0000\u0000\u0000\u0000Sixty-six cancer patients with COVID-19 were enrolled in this study. Among participants, 35 (53.03%) patients discharged and 31 (46.97%) patients died in hospital. Thirty-two (48.4%) patients suffered from hematologic and 34 (51.6%) from non-hematologic cancers. The most common comorbidities were hypertension (68.18%) and diabetes (56.06%). The most common symptoms among patients were rhinorrhea (59.1%), fever (54.5%) and dyspnea (48.4%), respectively. Diabetes (p= 0.00), hypoxemia (p= 0.005) and receiving chemotherapy or radiotherapy during the last three months (p= 0.022) were associated with a significantly greater risk of in-hospital mortality.\u0000\u0000\u0000\u0000Hypoxemia, diabetes and the time interval between chemotherapy/radiotherapy and hospitalization is associated with a higher risk of in-hospital mortality among cancer patients with COVID-19. These risk factors should be considered in clinical management hospitalized COVID19 patients who suffer from cancers. Regarding the risk factors may help to reduce in-hospital mortality and poor outcomes.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45599957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.2174/1573398x1801220518103551
N. Hussaini, J. Varon
{"title":"“COVID-19 is Here to Stay”","authors":"N. Hussaini, J. Varon","doi":"10.2174/1573398x1801220518103551","DOIUrl":"https://doi.org/10.2174/1573398x1801220518103551","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41720644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：